Skip to content
value.today
Beam Therapeutics Inc. logo

Beam Therapeutics Inc.

🇺🇸 Cambridge, Massachusetts, USAPharmaceuticalsFounded 2017
Total raised
$219 M
2 rounds on record
Latest round
$135 M
Nov 2018
First round on record
Feb 2018
Today
Went public
See the company page

Beam Therapeutics Inc. is listed today as Beam Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Beam Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2018$135 MNo. 2$50 to $250 million

Beam Therapeutics Inc.: Raise no. 2, Nov 2018

Investors in this round

27 investors had bought by the notice of Mar 26, 2019: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Beam Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$135 M of $135 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Evans · Executive Officer, Director
  • Carole Ho · Director
  • Kristina Burow · Director
  • Mark Fishman · Director
  • Michael Yi · Director
  • Robert Nelsen · Director
  • Stephen Knight · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Evans, Chief executive. Source: SEC Form D, newest notice filed Mar 26, 2019. Read the notice at the SEC.

equitySEC
Feb 2018$84 MNo. 1$50 to $250 million

Beam Therapeutics Inc.: Raise no. 1, Feb 2018

Investors in this round

21 investors had bought by the notice of Mar 26, 2019: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Beam Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$84 M of $84 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Evans · Executive Officer, Director
  • Carole Ho · Director
  • Kristina Burow · Director
  • Mark Fishman · Director
  • Michael Yi · Director
  • Robert Nelsen · Director
  • Stephen Knight · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Evans, Chief executive officer and director. Source: SEC Form D and 1 amendment, newest notice filed Mar 26, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Beam Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2019).

    SEC Form D · Mar 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2019

That is all the official record says: Beam Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Beam Therapeutics Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Beam Therapeutics Inc.
InvestorKindAmountRoundRoleSource
ARCH Venture Fund IX, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
ARCH Venture Fund IX Overage, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
ARCH Venture Partners IX, LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
ARCH Venture Partners IX, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
ARCH Venture Partners IX Overage, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Fmr LLCFund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Mark FishmanPersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2020)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 27 investors.

Largest shareholders today

Institutions holding Beam Therapeutics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Beam Therapeutics Inc.
NameRoleNamed in
John EvansExecutive officerMar 2019
Carole HoDirectorMar 2019
John EvansDirectorMar 2019
Kristina BurowDirectorMar 2019
Mark FishmanDirectorMar 2019
Michael YiDirectorMar 2019
Robert NelsenDirectorMar 2019
Stephen KnightDirectorMar 2019
Feng ZhangDirectorAug 2018
Robert NelsonDirectorAug 2018

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.